← FDA DRUG APPROVALS

FDA ANDA · ANDA076337

CYCLAFEM 1/35

Sponsor: PH HEALTH

APPLICATION
ANDA076337
TYPE
ANDA
ORIGINAL APPROVAL
2010-11-12
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CYCLAFEM 1/35Discontinued
ETHINYL ESTRADIOL 0.035MG, NORETHINDRONE 1MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 12 · standardAP
2022-03-16Labeling · Supplement 9 · standardAP
2022-03-16Labeling · Supplement 10 · standardAP
2015-04-13Labeling · Supplement 6 · standardAP
2014-08-04Manufacturing (CMC) · Supplement 7 · unknownAP
2014-01-28Manufacturing (CMC) · Supplement 1AP
2010-11-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →